Skip to main content

TCG Crossover — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

76
Companies
$14.2B
Total invested
$173.4M
Avg. check
14
Industries
Biotechnology 23Health Care 17Therapeutics 14Medical 13Pharmaceutical 10Life Science 4+8 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 76
ADARx Pharmaceuticals
February 2025

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

Biotechnology · San DiegoVenture - Series Unknown
Alkeus Pharmaceuticals
June 2023

Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.

Biotechnology · Cambridge$150.0M Series B
Century Therapeutics
January 2026

Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.

Biotechnology · Philadelphia$135.0M Post-IPO Equity
Beacon Therapeutics
January 2026

Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.

Biotechnology · Alachua$75.0M Series C
Aviceda Therapeutics
January 2025

Aviceda Therapeutics is a late-stage pre-clinical biotech company developing drugs for treating glyco-immune diseases.

Biotechnology · Cambridge$207.5M Series C
Synthekine
January 2023

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.

Biotechnology · Menlo Park$100.0M Series C
Tourmaline Bio
January 2024

Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.

Biotechnology · New York$172.5M Post-IPO Equity
Athira Pharma
December 2025

Athira Pharma is a clinical stage drug development company that specializes in biotechnology and pharmaceutical.

Biotechnology · Seattle$90.0M Post-IPO Equity
CG Oncology
December 2024

CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.

Biotechnology · Irvine$238.0M Post-IPO Equity
Immunovant
December 2025

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.

Biopharma · New York$550.0M Post-IPO Equity
Alpine Immune Sciences
November 2023

Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.

Biotechnology · Seattle$150.0M Post-IPO Equity
Cogent Biosciences
November 2025

Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.

Biotechnology · Waltham$200.0M Post-IPO Debt
Affinia Therapeutics
October 2025

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.

Biotechnology · Waltham$40.0M Series C
Cidara Therapeutics
October 2025

Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.

Biotechnology · San Diego$339.0M Grant
Disc Medicine
October 2025

Disc Medicine is a biopharmaceutical company that develops therapies for hematologic diseases and rare blood disorders.

Biotechnology · Watertown$225.0M Post-IPO Equity
Rapt Therapeutics
October 2025

Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.

Biotechnology · South San Francisco$250.0M Post-IPO Equity
ADC Therapeutics
October 2025

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

Biopharma · Lausanne$60.0M Post-IPO Equity
VectivBio
October 2022

VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.

Biotechnology · Basel$125.0M Post-IPO Equity
LB Pharmaceuticals
February 2026

LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.

Biopharma · New York$100.0M Post Ipo Equity
Perspective Therapeutics
February 2026

Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.

Health Care · Seattle$175.0M Post Ipo Equity
CORXEL Pharmaceuticals
January 2026

CORXEL Pharmaceuticals is a biotechnology company that develops science and medicines for underserved patients.

Biotechnology · Shanghai$287.0M Series D
Mirador Therapeutics
January 2026

Mirador Therapeutics develops precision medicines for immune-mediated diseases.

Biotechnology · San Diego$250.0M Series B
Mirum Pharmaceuticals
December 2025

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.

Biotechnology · Foster City$68.5M Post Ipo Equity
Structure Therapeutics
December 2025

Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

Biotechnology · South San Francisco$747.5M Post Ipo Equity

Where TCG Crossover invests

Biotechnology23
Health Care17
Therapeutics14
Medical13
Pharmaceutical10
Life Science4

About TCG Crossover's portfolio

How many companies has TCG Crossover invested in?

TCG Crossover has invested in 76 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does TCG Crossover invest in?

TCG Crossover's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 14 different industry categories.

What is TCG Crossover's largest investment?

Among tracked funding rounds, Structure Therapeutics received $747.5M in a Post Ipo Equity round. TCG Crossover's total known invested capital is $14.2B.

What is the average investment size for TCG Crossover?

TCG Crossover's average investment size is $173.4M across its portfolio of 76 companies.

What are TCG Crossover's most recent investments?

Recent TCG Crossover portfolio additions include ADARx Pharmaceuticals, Alkeus Pharmaceuticals, Century Therapeutics, Beacon Therapeutics, Aviceda Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 76 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →